BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Update

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 169,700 shares, a decrease of 39.3% from the April 30th total of 279,400 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is presently 0.1 days. Currently, 3.2% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of BriaCell Therapeutics in a report on Tuesday, April 22nd.

Hedge Funds Weigh In On BriaCell Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Cantor Fitzgerald L. P. bought a new stake in BriaCell Therapeutics during the fourth quarter worth about $32,000. Virtu Financial LLC acquired a new position in shares of BriaCell Therapeutics in the 4th quarter worth approximately $27,000. Finally, Vontobel Holding Ltd. grew its position in BriaCell Therapeutics by 37.5% during the 4th quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock worth $62,000 after acquiring an additional 30,000 shares during the last quarter. 15.42% of the stock is owned by institutional investors.

BriaCell Therapeutics Price Performance

Shares of BCTX stock opened at $3.42 on Monday. The stock’s fifty day simple moving average is $3.85 and its 200 day simple moving average is $6.02. BriaCell Therapeutics has a one year low of $2.81 and a one year high of $29.40. The firm has a market cap of $12.68 million, a price-to-earnings ratio of -0.26 and a beta of 1.38.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings data on Monday, March 17th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.39). On average, research analysts anticipate that BriaCell Therapeutics will post -2.45 earnings per share for the current year.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.